NZ514883A - Anti-bacterial vaccine compositions - Google Patents

Anti-bacterial vaccine compositions

Info

Publication number
NZ514883A
NZ514883A NZ514883A NZ51488300A NZ514883A NZ 514883 A NZ514883 A NZ 514883A NZ 514883 A NZ514883 A NZ 514883A NZ 51488300 A NZ51488300 A NZ 51488300A NZ 514883 A NZ514883 A NZ 514883A
Authority
NZ
New Zealand
Prior art keywords
atpg
gene
decreased
biological activity
activity
Prior art date
Application number
NZ514883A
Other languages
English (en)
Inventor
David E Lowery
Troy E Fuller
Michael J Kennedy
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of NZ514883A publication Critical patent/NZ514883A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NZ514883A 1999-04-09 2000-04-06 Anti-bacterial vaccine compositions NZ514883A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12868999P 1999-04-09 1999-04-09
US15345399P 1999-09-10 1999-09-10
PCT/US2000/009218 WO2000061724A2 (en) 1999-04-09 2000-04-06 Anti-bacterial vaccine compositions

Publications (1)

Publication Number Publication Date
NZ514883A true NZ514883A (en) 2004-03-26

Family

ID=26826843

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ514883A NZ514883A (en) 1999-04-09 2000-04-06 Anti-bacterial vaccine compositions
NZ530012A NZ530012A (en) 1999-04-09 2000-04-06 Anti-bacterial vaccine compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ530012A NZ530012A (en) 1999-04-09 2000-04-06 Anti-bacterial vaccine compositions

Country Status (14)

Country Link
US (5) US20070237793A1 (cg-RX-API-DMAC7.html)
EP (5) EP2281834B1 (cg-RX-API-DMAC7.html)
JP (4) JP4892134B2 (cg-RX-API-DMAC7.html)
KR (4) KR20010112937A (cg-RX-API-DMAC7.html)
CN (1) CN1351653A (cg-RX-API-DMAC7.html)
AR (1) AR029622A1 (cg-RX-API-DMAC7.html)
AU (2) AU780887B2 (cg-RX-API-DMAC7.html)
BR (1) BR0009663A (cg-RX-API-DMAC7.html)
CA (1) CA2366520C (cg-RX-API-DMAC7.html)
ES (2) ES2535961T3 (cg-RX-API-DMAC7.html)
HK (1) HK1045856A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA01010207A (cg-RX-API-DMAC7.html)
NZ (2) NZ514883A (cg-RX-API-DMAC7.html)
WO (1) WO2000061724A2 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ514883A (en) * 1999-04-09 2004-03-26 Upjohn Co Anti-bacterial vaccine compositions
US6790950B2 (en) 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
ATE418615T1 (de) 2001-09-26 2009-01-15 Kyowa Hakko Kogyo Kk Verfahren zur herstellung von galactosehaltigem komplexem zucker
ATE470674T1 (de) * 2002-04-05 2010-06-15 Merial Sas Abgeschwächte gramnegative bakterien
US7449178B2 (en) 2002-04-05 2008-11-11 Merial Limited Attenuated gram negative bacteria
GB0228691D0 (en) * 2002-12-09 2003-01-15 Imp College Innovations Ltd Bacterial virulence genes
ATE486936T1 (de) * 2003-03-05 2010-11-15 Chemo Sero Therapeut Res Inst Verfahren zur herstellung eines heterologen proteins in e. coli
ES2387827T3 (es) * 2006-10-05 2012-10-02 New York Blood Center, Inc. Péptidos antivirales helicoidales, de pequeño tamaño, terapéuticos estabilizados
US8937154B2 (en) 2006-10-05 2015-01-20 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
EP2283033A1 (en) 2008-05-06 2011-02-16 New York Blood Center Antiviral cell penetrating peptides
DE102011016772B8 (de) * 2011-04-12 2024-08-14 Mercedes-Benz Group AG Verfahren und Vorrichtung zur Überwachung zumindest eines Fahrzeuginsassen und Verfahren zum Betrieb zumindest einer Assistenzvorrichtung
US9757445B2 (en) 2013-11-01 2017-09-12 Merial Inc. Attenuated Pasteurella multocida vaccines and methods of making and use thereof
JP7183168B2 (ja) * 2017-02-10 2022-12-05 エピトピックス， エルエルシー タンパク質、及びＰａｓｔｅｕｒｅｌｌａタンパク質を含有する免疫化組成物、ならびに使用方法
TW202219269A (zh) * 2020-09-30 2022-05-16 美國農業部 新型多殺性巴斯德氏菌株及具有ｈｙａＣ與ｎａｎＰ缺失之疫苗
TW202214294A (zh) 2020-09-30 2022-04-16 美商碩騰服務公司 具有ｈｙａＣ及ｎａｎＰ缺失之新穎多殺性巴斯德氏菌株及疫苗
CN113567415A (zh) * 2021-07-05 2021-10-29 广西大学 表面增强拉曼散射结合免疫层析技术检测布鲁氏杆菌方法
CN115925536B (zh) * 2022-08-01 2025-02-28 北京农学院 靶向抑制DksA的小分子抑制剂和应用
CN116593695B (zh) * 2022-12-29 2025-08-05 重庆澳龙生物制品有限公司 一种牛多杀性巴氏杆菌荚膜a型elisa抗体检测试剂盒及其制备方法和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL52815A (en) * 1977-08-24 1983-03-31 Israel State Fowl cholera vaccine and process for producing an attenuated non-virulent strain of pasteurella multocida
US4735801A (en) * 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
US5077044A (en) * 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
DE3426532A1 (de) * 1984-07-18 1986-01-30 Gesellschaft für Biotechnologische Forschung mbH (GBF), 3300 Braunschweig Verwendung einer dna-sequenz zur expression sowie dna-struktur und expressionsvektor mit der dna-sequenz
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4877612A (en) 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
DK166762B1 (da) 1986-01-14 1993-07-12 Nederlanden Staat Fremgangsmaade til fremstilling af immunogenkomplekser og farmaceutisk sammensaetning indeholdende saadanne komplekser
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
CA1340522C (en) 1987-03-10 1999-05-04 Heinz Dobeli Fusion proteins containing neighbouring histidines for improved purification
IL86583A0 (en) * 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5376369A (en) * 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
DK46693D0 (cg-RX-API-DMAC7.html) * 1993-04-23 1993-04-23 Novo Nordisk As
DE69229221T2 (de) * 1991-03-05 1999-09-23 The Wellcome Foundation Ltd., Greenford Expression rekombinanter proteine in attenuierten bakterien
US5840312A (en) * 1991-05-02 1998-11-24 Institut Pasteur Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein
JPH08503136A (ja) * 1992-11-06 1996-04-09 リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ Ｐ．ｍｕｌｔｏｃｉｄａによるパスツレラ症に対する感染防御剤
US5585277A (en) 1993-06-21 1996-12-17 Scriptgen Pharmaceuticals, Inc. Screening method for identifying ligands for target proteins
US5587305A (en) * 1993-12-06 1996-12-24 The United States Of America As Represented By The Department Of Agriculture Pasteurella haemolytica transformants
WO1995020652A1 (de) 1994-01-28 1995-08-03 Medigene Gmbh Verfahren zur bestimmung der aktivität eines regulatorischen faktors sowie verwendung dieses verfahrens
US5888783A (en) * 1994-08-30 1999-03-30 Ajinomoto Co., Inc. Methods for producing L-valine and L-leucine
ES2178101T3 (es) * 1994-12-09 2002-12-16 Imp College Innovations Ltd Genes de virulencia en la region vgc2 de salmonella.
CA2170839A1 (en) * 1995-03-01 1996-09-02 Janet Macinnes Bacterial preparations, method for producing same, and their use as vaccines
US6355450B1 (en) * 1995-04-21 2002-03-12 Human Genome Sciences, Inc. Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
US5994066A (en) * 1995-09-11 1999-11-30 Infectio Diagnostic, Inc. Species-specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial pathogens and associated antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories
US5925354A (en) * 1995-11-30 1999-07-20 Michigan State University Riboflavin mutants as vaccines against Actinobacillus pleuropneumoniae
US5840556A (en) * 1996-05-08 1998-11-24 The United States Of America As Represented By The Department Of Agriculture Molecular genetic construction of vaccine strains of pasteurellaceae
ZA974809B (en) * 1996-05-31 1998-01-23 Akzo Nobel Nv Live attenuated RTX-producing bacteria of the family pasteurellaceae.
US6020474A (en) * 1997-01-15 2000-02-01 Incyte Pharmaceuticals, Inc. ATP synthase subunits
US6673538B1 (en) * 1997-07-25 2004-01-06 The Trustees Of Boston University Methods and compositions for designing vaccines
NZ514883A (en) * 1999-04-09 2004-03-26 Upjohn Co Anti-bacterial vaccine compositions
US6790950B2 (en) * 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
AU7131600A (en) * 1999-06-21 2001-01-09 North Carolina State University Acid-inducible promoters for gene expression
AU4204800A (en) * 1999-07-12 2001-01-30 Xoma Technology Ltd. Method to identify inhibitors f1/f0 atpase

Also Published As

Publication number Publication date
US20120148625A1 (en) 2012-06-14
EP2281834A2 (en) 2011-02-09
WO2000061724A2 (en) 2000-10-19
MXPA01010207A (es) 2003-07-21
JP2010284165A (ja) 2010-12-24
CA2366520A1 (en) 2000-10-19
KR20010112937A (ko) 2001-12-22
KR20060116041A (ko) 2006-11-13
AU2005203189A1 (en) 2005-08-18
NZ530012A (en) 2005-10-28
EP1860117A3 (en) 2008-09-03
AU780887B2 (en) 2005-04-21
EP2281835A3 (en) 2011-11-23
BR0009663A (pt) 2002-04-09
JP5973634B2 (ja) 2016-08-23
US20090202594A1 (en) 2009-08-13
EP1171577A2 (en) 2002-01-16
EP2281835A2 (en) 2011-02-09
CN1351653A (zh) 2002-05-29
JP2002541790A (ja) 2002-12-10
US20100322975A1 (en) 2010-12-23
AU2005203189B2 (en) 2007-12-20
JP2016019528A (ja) 2016-02-04
EP2281835B1 (en) 2013-11-06
ES2439645T3 (es) 2014-01-24
ES2535961T3 (es) 2015-05-19
EP2281834B1 (en) 2015-03-04
HK1045856A1 (zh) 2002-12-13
US20070237793A1 (en) 2007-10-11
EP2281833A2 (en) 2011-02-09
EP2281833B1 (en) 2014-07-02
AR029622A1 (es) 2003-07-10
US7763262B2 (en) 2010-07-27
EP2281834A3 (en) 2011-11-23
US9289486B2 (en) 2016-03-22
KR20060134225A (ko) 2006-12-27
JP4892134B2 (ja) 2012-03-07
EP1860117A2 (en) 2007-11-28
US20150182615A1 (en) 2015-07-02
AU4077600A (en) 2000-11-14
JP2013121347A (ja) 2013-06-20
WO2000061724A3 (en) 2001-02-01
US8974798B2 (en) 2015-03-10
CA2366520C (en) 2013-10-01
KR20070011622A (ko) 2007-01-24
EP2281833A3 (en) 2011-11-30
JP5377433B2 (ja) 2013-12-25

Similar Documents

Publication Publication Date Title
NZ514883A (en) Anti-bacterial vaccine compositions
Assih et al. Stenotrophomonas acidaminiphila sp. nov., a strictly aerobic bacterium isolated from an upflow anaerobic sludge blanket (UASB) reactor.
Young et al. A bifunctional urease enhances survival of pathogenic Yersinia enterocolitica and Morganella morganii at low pH
Marshall et al. Glycopeptide antibiotic resistance genes in glycopeptide-producing organisms
Archer et al. Characterization of IS1272, an insertion sequence-like element from Staphylococcus haemolyticus
SG165157A1 (en) Identification of genes
EP1167542A3 (en) Probe for diagnosing infectious disease arising from Enterococcus faecalis
WO1999033960A3 (en) Proteases from gram positive organisms
WO1999034003A3 (en) Proteases from gram positive organisms
KR20060121212A (ko) 세린 프로테아제, 세린 효소들을 인코딩하는 핵산 및 이를편입시킨 벡터 및 숙주 세포
AR035745A1 (es) Bacteria gram-negativa, una composicion inmunogena, una composicion para vacunas, un metodo para producir un mutante, un polinucleotido de pasteurellaceae purificado y aislado, un vector, una celula transformada establemente o transfectada, metodo para producir un polipeptido recombinante, anticuerp
MacKinnon et al. Identification and characterization of IS1476, an insertion sequence-like element that disrupts VanY function in a vancomycin-resistant Enterococcus faecium strain
AU2003223447A1 (en) Attenuated gram negative bacteria
Stepanović et al. Brain abscess due to Actinobacillus actinomycetemcomitans: Case report
EP1108786A4 (en) NEW COLLECTIN
EP1047710B1 (de) Orotidin-5'-phosphatdecarboxylase-gen, genkonstrukt enthaltend dieses gen und seine verwendung
Robinson et al. X chromosome evolution in the suni and eland antelope: detection of homologous regions by fluorescence in situ hybridization and G-banding
PT1164190E (pt) Gene da artrite reumatóide e método para o diagnóstico da artrite reumatóide
PT1350796E (pt) Bactérias gram-negativas atenuadas
ATE318933T1 (de) Nukleinsäurefragmente zur identifizierung von dechlorierenden bakterien
GB9724627D0 (en) Gram positive microorganism formate pathway
GB9321302D0 (en) Enzyme
GB9321325D0 (en) Microorganism and its use
TW200700555A (en) Saponin-decomposing enzyme, gene thereof and large-scale production system for producing soyasapogenol b
AU710730B2 (en) Method to predict active growth of bacteria adhered to a surface

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)